Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPESTRY: bintrafusp alfa with definitive chemoradiation for esophageal squamous cell carcinoma
NL-OMON60826Phase 2Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bintrafusp alfa in Esophageal Squamous Cell Carcinoma (ESCC) and gastroesophageal junction squamous cell carcinoma, sponsored by Amsterdam University Medical Center. Primary endpoint: Feasibility. Started Jun 2024; status: active, not recruiting.
02
Drugs
bintrafusp alfa
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)gastroesophageal junction squamous cell carcinoma
Beyond the preview
Go deeper on NL-OMON60826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60826.